麗珠醫藥(01513.HK):天津同仁堂IPO申請已恢復審核
格隆匯3月31日丨麗珠醫藥(01513.HK)發佈公吿,有關公司受讓天津同仁堂40.00%股權。公司獲悉,公司參股公司天津同仁堂於近日收到深交所下發的《津同仁_IPO_恢復申請提醒》。因天津同仁堂申請首次公開發行股票並在創業板上市聘請的會計師信永中和會計師事務所(特殊普通合夥)已出具複核報吿,根據《深圳證券交易所創業板股票發行上市審核規則》第六十六條的相關規定,深交所於2022年3月30日恢復天津同仁堂本次發行上市審核。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.